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A recently released study powerfully 
suggests that doctor resistance to 
prescribing highly effective isoniazid 
preventive therapy (IPT) to their 
TB-negative HIV patients is contributing 
to the national TB epidemic.
Until now, much to the chagrin of the HIV 
Clinicians Society of Southern Africa, there 
has been significant anecdotal evidence about 
clinician resistance across the country to use 
the World Health Organization (WHO)-
recommended preventive TB therapy. The 
qualitative study is the first to produce actual 
evidence of doctor ignorance and/or fears 
of IPT in spite of exhortations, including 
from the national health minister, Dr Aaron 
Motsoaledi, to make it standard practice.
Isoniazid, also known as 
isonicotinylhydrazine (INH), is an organic 
compound that is the first-line medication 
in prevention and treatment of TB. It is 
a simple and cost-effective measure that, 
most importantly, prevents TB bacteria from 
becoming active if present. The drug is 
never used on its own to treat (as against 
to prevent) active TB because resistance 
quickly develops.
The ‘Barriers to IPT use’ study setting 
was the Aurum Institute, an internationally 
recognised, not-for-profit specialist research 
and health systems management organisation 
set up by Anglo-Gold Ashanti in 1998, but now 
an independent body. The institute specialises 
in TB and HIV prevention, treatment and care 
and delivers ART and prophylaxis, including 
IPT, free of charge.
Aurum CEO, Dr Gavin Churchyard, and his 
colleagues collaborated with researchers from 
the London School of Hygiene and Tropical 
Medicine to probe why IPT was so seldom 
prescribed in the public clinics under scrutiny.1 
They concluded that a change in health care 
worker perception was needed if IPT was to be 
widely used in the public sector.
Exhaustive interviews with 22 clinic staff 
and 20 patients showed that the mindset and 
a lack of experience among physicians were 
the biggest barriers to implementation – well 
ahead of the unwieldy systemic need to refer 
patients to separate clinics for TB screening. 
The requirement to rule out active TB prior 
to beginning IPT was perceived as a critical 
barrier by most clinic staff.
Prescribers were unaware of the benefits 
of IPT, unclear about the guidelines and 
believed that existing screening tools were 
inaccurate in HIV-infected individuals. 
The study found that clinic staff prescribed 
IPT according to inconsistent criteria. Only 
one site prescribed according to Aurum 
guidelines. Two sites used IPT in patients 
with CD4 cell counts less than 200 and one 
site thought IPT should only be used in 
patients on antiretroviral treatment (ART). 
Although all doctors had heard of IPT, 
several were either unaware of its efficacy in 
preventing TB or believed that the evidence 
was equivocal.
Perceived operational barriers included a 
number of practical issues that staff believed 
were prohibitive to the use of IPT. One 
was that using isoniazid without other TB 
medications would induce drug resistance, 
particularly in the South African context of 
multidrug-resistant (MDR) and extensively 
drug-resistant (XDR) TB. The consensus 
from current literature is that IPT does 
not promote isoniazid resistance.1 Another 
perception barrier was the belief that the 
high prevalence of TB meant that starting 
empirical courses of full treatment for TB 
was safer and offered greater benefit than 
prophylaxis.
TB-exclusive screening a real 
problem
All nine doctors who took part in a focus group 
discussion cited the need to screen for and rule 
out active TB prior to commencing IPT as 
a major concern, arguing that false-negative 
sputum tests and chest radiography, as well as 
atypical presentations among those infected 
with HIV, made TB screening difficult.
One ‘low IPT usage’ doctor was quoted in 
the Aurum research paper as saying: ‘Testing 
for TB is difficult – it’s paucibacillary, 
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extrapulmonary. Standard pulmonary TB is 
not more than 30% of our patients. Sputum, 
abscesses, lymph nodes, X-rays are very 
often negative. I would never use INH on my 
patients, for this reason alone.’
The researchers concede that most 
investigations for TB screening were 
performed offsite (only one clinic had chest 
radiography and none could test sputum on 
site). They reported clinic staff as frequently 
citing a lack of co-ordination between TB 
and HIV activities as a barrier to starting 
patients on IPT.
However, the researchers said that in a 
programme that had promoted IPT since its 
inception in 1999, the lack of clarity around 
its benefits among health care workers was 
‘all the more remarkable’. The research team 
speculated, without naming anyone, that 
public opposition to IPT ‘among some senior 
clinicians in South Africa’ was the reason for 
the physician resistance they encountered. 
Policy clarification and dissemination of 
accurate information were urgently required 
and well-chosen local opinion leaders were 
needed to act as ‘IPT champions’. The authors 
said a much greater effort was needed to 
achieve widespread IPT roll-out. Overcoming 
operational barriers, while necessary, was not 
enough without a parallel bid to change the 
perceptions of health care workers.
Dr Francois Venter, President of the HIV 
Clinicians Society of Southern Africa, said 
that within the wider South African context 
IPT was ‘more of a hostage to a bad system 
than to physicians’. Agreeing that education 
of physicians was important to counter low 
IPT usage, he said that far more critically 
‘we need to think harder about what carrots 
we can dangle to get healthy HIV-positive 
people back into the system’.
IPT was ‘great’ for preventing TB in 
patients who did not need ARVs, ‘but we’ve 
been dreadful in retaining them in the 
system – the problem is the system required 
to give IPT is grossly dysfunctional’.
Even if ‘the perfect tablet (with no 
resistance) was available, these folk would 
still not come into the system. They don’t 
see any benefits, particularly when the 
health system is unfriendly.’ Venter said that 
nationally, ‘I don’t think health care worker 
fear (of IPT) is the biggest issue – nor is it 
insurmountable,’ he added.
WHO fully backs IPT
Dr Gottfried Hirnschall, Director of 
WHO’s HIV/AIDS Department, said full 
implementation of the ‘three I’s for HIV/TB 
strategy in collaboration with all partners 
was urgently needed’.
IPT, intensified TB screening and 
infection control for TB were vital as part of 
comprehensive HIV services. Hirnschall said 
key recommendations from new scientific 
evidence were that all children and adults 
living with HIV, including pregnant women 
and those on ART, should receive IPT. 
Isoniazid should be provided for 6 - 36 
months or as a lifelong treatment in settings 
with high HIV and TB prevalence (89% of 
miners are infected with TB). People living 
with HIV who may have TB symptoms 
should be further screened for active TB or 
other conditions so they could access the 
appropriate treatments.
Added Dr Mario Raviglione, WHO’s 
Stop TB department chief: ‘We need to 
break the chain that links TB and HIV, 
leading to death’. The WHO would support 
all countries and communities to implement 
the new guidelines.
The potential preventive efficacy of 
isoniazid is best illustrated by a proven 36% 
rise in the risk of TB for every drop of 100 
CD4 cells/µl among HIV-positive people.
Other studies conducted among miners 
by Churchyard and his colleagues included 
the Thibela TB study, which is evaluating 
the efficacy of community-wide IPT, 
which was the focal point for the much-
acclaimed findings, first presented at the 
2nd Consortium to Respond Effectively to 
the AIDS/TB epidemic, (CREATE), in Cape 
Town during the first week of November 
last year.
A total of 24 221 miners were started on 
IPT from April 2006, the largest number 
of participants ever enrolled into a trial of 
IPT globally. Knowledge among miners was 
poor, but once the concept was popularised 
through a highly successful and sophisticated 
awareness campaign across mine shafts, mine 
unions actually threatened to strike unless the 
programme was implemented.2 Final efficacy 
results are expected early in 2012.
One sub-study found that adding chest 
radiography to symptom screening increased 
by 2.5 fold the number of definite TB cases 
detected.3 Only 0.2% of active TB cases among 
19 609 individuals correctly screened for TB 
who started IPT and had more than 90 days 
of follow up, were missed.3 The researchers 
also found that the risk of adverse events, 
particularly hepatotoxicity, was very low in 
the mining populations they worked with.4 
In a separate study among platinum miners 
the research team found that mortality among 
people receiving IPT with or prior to ART 
inception was lower, supporting the routine 
use of IPT in conjunction with ART.5
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A boisterous trio of miners seemingly unphased by 
the daily occupational disease hazards they face.
The lively cast of the popular TV soapie, ‘Emzini 
Wezinsizwa,’ about the daily lives of mine hostel 
dwellers, helped the Aurum Institute popularise 
its Thibela TB prevention programme – with 
huge success.
